CONSTRUCTION OF AN ANTIBODY ENGINEERING LABORATORY

分子医学和免疫学中心（CMMI）申请资金，为最先进的抗体工程实验室计划改造空间，用于研究和开发单克隆抗体，免疫缀合物和相关衍生物，以支持CMMI的临床试验。CMMI成立于1983年，目前位于新泽西的贝尔维尔镇，是一个非营利的癌症研究和治疗中心。为了实现其长期目标，将被指定为NCI癌症中心。CMMI正在翻新前埃塞克斯县隔离医院大楼的20万总平方英尺（gsf）。在扩建后的设施中，CMMI计划建立40至50个主要的研究实验室，以35名高级科学家为核心，预计员工总数为300人，近55，000 gsf致力于门诊和住院临床试验。抗体工程实验室计划旨在容纳两个主要部门：（1）分子生物学实验室和（2）抗体和肽化学实验室。该实验室计划将涵盖约20，000平方英尺的总面积，并将专注于研究，开发和转移到临床试验人源化抗体，重新设计的抗体，多特异性抗体和与放射性核素，药物酶和毒素连接的肽用于癌症的诊断和治疗。CMMI的研究项目是抗体研究领域最大的持续项目，已经发表了500多篇同行评议的文章，包括六次会议的出版物。为了确保CMMI在抗体检测和癌症治疗方面的生产力和领导作用的延续，抗体工程实验室计划的空间改造是CMMI在生物治疗领域建立主要临床癌症中心计划的重要组成部分。事实上，目前所有由国家癌症研究所资助的研究人员都在生物治疗领域获奖，主要是在使用单克隆抗体进行放射免疫检测、放射免疫治疗和其他抗体靶向方法方面。该计划将允许用于诊断和治疗癌症的新型生物制剂的初步开发，为当前项目的支持以及新项目的扩展提供必要的研究，最重要的是，允许治疗II期研究的疗效，并最终通过III期试验使患者受益。

The Center for Molecular Medicine and Immunology (CMMI) requests funds to renovate space for a state-of-the-art Antibody Engineering Laboratory Program for the research and development of monoclonal antibodies, immunoconjugates, and related derivatives in support of CMMI's clinical trials. CMMI, established in 1983 and presently located in the Township of Belleville, New Jersey, is a not-for-profit cancer research and treatment center. To accomplish its long-term goals is to be designated as an NCI cancer center. CMMI is renovating the former Essex County Isolation Hospital Building of 200,000 gross square feet (gsf). In the expanded facility, CMMI has planned 40 to 50 major research laboratories to be centered around a nucleus of 35 senior scientists, with the total staff projected at 300 3empoyees and with nearly 55,000 gsf dedicated to outpatient and inpatient clinical trials. The Antibody Engineering Laboratory Program is intended to house two major divisions: (1) Molecular Biology Laboratories and (2) Antibody and Peptide Chemistry Laboratories. The laboratory program will encompass a total area of approximately 20,000 square feet and will focus on researching, developing and transferring to clinical trials humanized antibodies, re-engineered antibodies, multi-specific antibodies and peptides linked to radionuclides, drugs enzymes and toxins for the diagnosis and treatment of cancer. CMMI's research program, which is the largest continuing program in the field of antibody research, has resulted in over 500 peer-reviewed articles, including the publication of six conferences. To ensure the continuation of CMMI's productivity and leadership role in antibody detection and treatment of cancer, renovation of space for an Antibody Engineering Laboratory Program is an important component of a major CMMI initiative to establish a major clinical cancer center program in the area of biological therapy. Indeed, all of the current NCI-funded investigators have awards in areas of biological therapy, primarily in the use of monoclonal antibodies for radioimmunodetection, radioimmunotherapy and other antibody-targeting methodologies. The Program will allow the initial development of novel biological agents for the diagnosis and treatment of cancer, provide the research necessary for the support of current projects as well as for the expansion of new projects, and most importantly, to allow for efficacy of treatment Phase II studies, and eventually to benefit patients through Phase III trials.